hVIVO PLC - London-based specialist contract research organisation providing testing for infectious and respiratory vaccines - Says revenue in the six months to June 30 grew by 52% to £27.3 million from £18.0 million a year prior. Earnings before interest, depreciation and amortisation margin is around 19%, higher than 13% the year before. Adds order book at June 30 was £78 million, up 11% from £70 million in the first half of 2022. Notes full-year revenue remains in line with expectations of £53 million, as well as Ebitda margins in mid to high teens.

Chief Executive Officer Yamin Khan says: ‘I take pride in what the team has achieved and admire their determination to continue our growth path. It has also been pleasing to see a number of our clients receive positive outcomes as a result of conducting challenge trials with us. Coupled with our current track record of operational delivery, the board is confident that the group will achieve its full year revenue and Ebitda expectations.’

Current stock price: 16.55 pence, up 3.4% on Wednesday

12-month change: up 58%

Copyright 2023 Alliance News Ltd. All Rights Reserved.